National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing the price of nearly 900 cancer medicine brands by up to 70%-93%. However, for comprehensive cancer care in India, price regulation might not be enough. Cancer care is one of the steepest barriers to equitable healthcare in India.